Citations

Clear

151 citation(s) found for "Mathieu, D".

Outcomes of stereotactic radiosurgery for pilocytic astrocytoma: an international multiinstitutional study
Murphy, Erin S. , Parsai, Shireen , Kano, Hideyuki , Sheehan, Jason P. , Martínez‐Álvarez, Roberto , Martínez-Moreno, Nuria, Kondziolka, Douglas , Liščák, Roman , Mathieu, David , Lee, Cheng‐Chia , Lee, John , McShane, Brendan, Fang, Fang , Barnett, Gene H. , Mathieu, David , Kondziolka, Douglas , Martinez-Alvarez, Roberto, Šimonová, Gabriela , Yang, Huai‐Che , Trifiletti, Daniel M. , Sharma, Mayur

Mayo Clinic

Journal of Neurosurgery | December 13, 2019 | Volume: 134 | Issue: 1 | Pages: 162-170

10.3171/2019.9.jns191335 | PMID 31783364 Get It

OBJECTIVE The current standard initial therapy for pilocytic astrocytoma is maximal safe resection. Radiation therapy is considered for residual, recurrent, or unresectable pilocytic astrocytomas. However, the optimal radiation strategy has not yet been established. Here, the authors describe the outcomes of stereotactic radiosurgery (SRS) for pilocytic astrocytoma in a large multiinstitutional cohort. METHODS An institutional review board–approved multiinstitutional database of patients treated with Gamma Knife radiosurgery (GKRS) between 1990 and 2016 was queried. Data were gathered from 9 participating International Radiosurgery Research Foundation (IRRF) centers. Patients with a histological diagnosis of pilocytic astrocytoma treated using a single session of GKRS and with at least 6 months of follow-up were included in the analysis. RESULTS A total of 141 patients were analyzed in the study. The median patient age was 14 years (range 2–84 years) at the time of GKRS. The median follow-up was 67.3 months. Thirty-nine percent of patients underwent SRS as the initial therapy, whereas 61% underwent SRS as salvage treatment. The median tumor volume was 3.45 cm 3 . The tumor location was the brainstem in 30% of cases, with a nonbrainstem location in the remainder. Five- and 10-year overall survival rates at the last follow-up were 95.7% and 92.5%, respectively. Five- and 10-year progression-free survival (PFS) rates were 74.0% and 69.7%, respectively. On univariate analysis, an age < 18 years, tumor volumes < 4.5 cm 3 , and no prior radiotherapy or chemotherapy were identified as positive prognostic factors for improved PFS. On multivariate analysis, only prior radiotherapy was significant for worse PFS. CONCLUSIONS This represents the largest study of single-session GKRS for pilocytic astrocytoma to date. Favorable long-term PFS and overall survival were observed with GKRS. Further prospective studies should be performed to evaluate appropriate radiosurgery dosing, timing, and sequencing of treatment along with their impact on toxicity and the quality of life of patients with pilocytic astrocytoma.
Aging reduces succinate dehydrogenase activity in rat type IIx/IIb diaphragm muscle fibers
Fogarty, Matthew J. , Mathieu, Natalia M. , Marin Mathieu, Natalia, Marin Mathieu, Natalia , Mantilla, Carlos B. , Sieck, Gary C. , Fogarty, Matthew J

Mayo Clinic

Journal of Applied Physiology | November 27, 2019 | Volume: 128 | Issue: 1 | Pages: 70-77

10.1152/japplphysiol.00644.2019 | PMID 31774353 Get It

In aged rats, diaphragm muscle (DIAm) reduced specific force and fiber cross-sectional area, sarcopenia, is selective for vulnerable type IIx and/or IIb DIAm fibers, with type I and IIa fibers being resilient. In humans, the oxidative capacity [as measured by maximum succinate dehydrogenase (SDH max ) activity] of fast-type muscle is reduced with aging, with slow-type muscle being unaffected. We hypothesized that in aged Fischer rat DIAm exhibiting sarcopenia, reduced SDH max activity would occur in type IIx and/or IIb fibers. Rats obtained from the NIA colony (6, 18, and 24 mo old) were euthanized, and ~2-mm-wide DIAm strips were obtained. For SDH max and fiber type assessments, DIAm strips were stretched (approximately optimal length), fresh frozen in isopentane, and sectioned on a cryostat at 6 μm. SDH max , quantified by intensity of nitroblue tetrazolium diformazan precipitation, was assessed in a fiber type-specific manner by comparing serial sections labeled with myosin heavy chain (MyHC) antibodies differentiating type I (MyHC Slow ), IIa (MyHC 2A ), and IIx and/or IIb fibers. Isometric DIAm force and fatigue were assessed in DIAm strips by muscle stimulation with supramaximal pulses at a variety of frequencies (5–100 Hz) delivered in 1-s trains. By 24 mo, DIAm sarcopenia was apparent and SDH max in type IIx and/or IIb fibers activity was reduced ~35% compared with 6-mo-old control DIAm. These results underscore the remarkable fiber type selectivity of type IIx and/or IIb fibers to age-associated perturbations and suggest that reduced mitochondrial oxidative capacity is associated with DIAm sarcopenia. NEW & NOTEWORTHY We examined the oxidative capacity as measured by maximum succinate dehydrogenase activity in older (18 or 24 mo old) Fischer 344 rat diaphragm muscle (DIAm) compared with young rats (6 mo old). In 24-mo-old rats, SDH activity was reduced in type IIx/b DIAm fibers. These SDH changes were concomitant with sarcopenia (reduced specific force and atrophy of type IIx/b DIAm fibers) at 24 mo old. At 18 mo old, there was no change in SDH activity and no evidence of sarcopenia.
The C Protein Is Recruited to Measles Virus Ribonucleocapsids by the Phosphoprotein
Pfaller, Christian K. , Bloyet, Louis-Marie , Donohue, Ryan C. , Bartemes, William P., Yousaf, Iris, Urzua, Érica, Clavière, Mathieu, Zachary, Marie , d’Autume, Valentin de Masson , Carson, Sandra E. , Schieferecke, Adam J. , Meyer, Alyssa J. , Gerlier, Denis , Cattaneo, Roberto , Huff, Amanda L. , Carson, Sandra, Gerlier, Denis , Cattaneo, Roberto , Pfaller, Christian K

Mayo Clinic

Journal of Virology | November 18, 2019 | Volume: 94 | Issue: 4 | Pages: No page available

10.1128/jvi.01733-19 | PMID 31748390 Get It

Replication of negative-strand RNA viruses relies on two components: a helical ribonucleocapsid and an RNA-dependent RNA polymerase composed of a catalytic subunit, the L protein, and a cofactor, the P protein. We show that the measles virus (MeV) C protein is an additional component of the replication complex. We provide evidence that the C protein is recruited to the ribonucleocapsid by the P protein and map the interacting segments of both C and P proteins. We conclude that the primary function of MeV C is to improve polymerase processivity and accuracy, rather than uniquely to antagonize the type I interferon response. Since most viruses of the Paramyxoviridae family express C proteins, their primary function may be conserved.
A Complementary Role of High Throughput Sequencing and Multiparameter Cytometry for Minimal Residual Disease (MRD) Detection in Chronic Lymphocytic Leukemia (CLL):an European Research Initiative (ERIC) Study
Rawstron, Andy C. , Fazi, Claudia, Delgado, Julio , Cymbalista, Florence, Tute, Ruth M. de , Liptrot, Stuart, O’Brien, David , Dobber, Johan A., Kater, Arnon P. , Gambell, Peter, Westerman, David , Soosapilla, Asha, Lozanski, Gerard , Lin, Ke , Pettitt, Andrew R. , Brachtl, Gabi, Williamson, David, Sanders, Catherine , Robins, Harlan , Boysen, Justin C. , Hanson, Curtis A. , Stetler‐Stevenson, Maryalice , Rassenti, Laura Z., Broome, H. Elizabeth, Hauwel, Mathieu , Craig, Fiona E. , Josep, Nomdedeu, Moreno, Carol , Stehlíková, Olga , Doubek, Michael , Pospı́šilová, Šárka , Kreuzer, Karl‐Anton, Hallek, Michael , Montserrat, Emili , Villamor, Neus , Letestu, Rémi , Palacio, Carlos , Bosch, Francesc , Špaček, Martin , Mulligan, Stephen P. , Egle, Alexander , Shanafelt, Tait D. , Jorgensen, Jeffrey L. , Wierda, William G. , Yuan, Constance M. , Kipps, Thomas J. , Marinov, Iuri , Hillmen, Peter , Ghia, Paolo

Mayo Clinic

Blood | October 10, 2019 | Volume: 124 | Issue: 21 | Pages: 1976-1976

10.1182/blood.v124.21.1976.1976 Get It

Abstract BACKGROUND. The detection of minimal residual disease (MRD) at the level of 0.01%/10-4 or above is a strong independent predictor of reduced progression-free (PFS) and overall survival (OS) in patients with CLL treated with chemoimmunotherapy. Although newer agents such as B-cell receptor pathway inhibitors can result in prolonged survival without achieving complete response, there remains a important role for MRD analysis in assessing therapeutic strategies aimed at disease eradication and cure. This is particularly important in front-line trials for fit patients which now require at least five years of follow-up if PFS is used as an endpoint. The feasibility of using MRD as a surrogate or intermediate endpoint for accelerated approval of new treatments is under review by regulatory agencies but further prospective validation is required. At the same time technology is rapidly evolving and high-throughput sequencing (HTS) technologies now detect MRD at the 0.0001%/10-6 level. It is therefore important to determine the most effective approaches for quantifying MRD that are compatible with previous studies but sufficiently sensitive for current treatments. AIMS. This collaborative project had two objectives. First, to identify the simplest and most flexible flow cytometry panel capable of detecting MRD at the 0.01%/10-4 or lower, that is compatible with published data and independent of instrument/reagent manufacturer. Second, to compare the flow cytometry approach with HTS analysis using the ClonoSEQ assay (Adaptive Biotechnologies, Seattle, WA). METHODS AND RESULTS. A core panel of antibodies for MRD detection was identified by testing an 8-marker combination in 52 samples (27 post-treatment and 25 dilution study) and re-analysing data with serial exclusion of single markers to determine redundancy. A 1-tube core panel of CD19, CD20, CD5, CD43, CD79b, and CD81 was identified and validated against the previously published 2-tube 6-marker and 4-tube 4-marker ERIC panels in 76 samples (19 post-treatment and 57 dilution study). The results showed good concordance (for log-transformed data above the LoQ, linearity=0.977, Pearson correlation co-efficient=0.983, average difference=0.026 log, 95% limit of agreement 0.20log) and a limit of detection of 0.001%/10-5 for the 1-tube core panel. Inter-operator variation was similar to CML MRD monitoring with both experienced operators, or inexperienced cytometrists after ~1 hour of specific education, achieving a 95% limit of agreement less than 0.3log in samples with MRD levels ranging from 0.0001 – 100%. The flow cytometry approach was compared with the ClonoSEQ HTS assay in 109 samples (21 dilution study and 88 post-treatment samples, complete data currently available on 13/88). The assay was applicable to the vast majority CLL patients, often with two clonal markers. There was 94% concordance at the 0.01% (10-4) threshold (15 samples with ≥0.01% CLL by both methods, 14 samples with <0.01% by both methods, 1 sample with 0.03% CLL by HTS and <0.003% CLL by flow cytometry, and 1 sample with 0.005% CLL by HTS and 0.012% by flow cytometry. HTS detected CLL IGH sequences in 22% (7/31) samples with no detectable CLL cells by flow cytometry (i.e. CLL level 0.0001-0.001%, 3/13 patient samples and 4/18 dilution samples). HTS demonstrated a relatively high variability in quantification, as seen in previous studies, but with a clear superiority in the limit of detection and good linearity (linearity=0.905, Pearson correlation co-efficient=0.870, average difference=0.078 log, 95% limit of agreement 1.5 log). CONCLUSIONS. The 1-tube 6-marker flow cytometry core panel is compatible with published studies, manufacturer-independent and flexible, providing directly quantitative results to 0.001%/10-5 without requiring a pre-treatment sample. HTS requires further work to standardise the quantitative analysis and prospective validation but the ClonoSEQ assay is applicable to >95% of CLL patients, does not require viable cells and is extremely sensitive, detecting residual disease in a significant proportion of cases with <0.01% CLL. The results indicate that flow cytometry and HTS are complementary technologies with a combined approach offering the most reliable way of quantifying CLL at the 0.01%/10-4 threshold while allowing higher sensitivity in clinical trials aimed at disease eradication. Disclosures Rawstron: Roche: Honoraria; Biogen Idec: Consultancy; Gilead: Consultancy, Honoraria; Abbvie: Honoraria; BD Biosciences: Intrasure reagent Patents & Royalties; Celgene: Honoraria; GSK: Honoraria. Williamson:Adaptive Biotechnologies: Employment, Equity Ownership. Sanders:Adaptive Biotechnologies: Employment, Equity Ownership. Robins:Adaptive Biotechnologies: Consultancy, Equity Ownership, Patents & Royalties. Hallek:Celgene: Honoraria, Research Funding; Mundipharma: Honoraria, Research Funding; Roche: Honoraria, Research Funding; Janssen: Honoraria, Research Funding; GSK: Honoraria; Gilead: Honoraria. Hillmen:Roche: Honoraria, Research Funding; GSK: Honoraria, Research Funding; Janssen: Honoraria, Research Funding; Pharmacyclics: Honoraria, Research Funding; Gilead: Honoraria, Research Funding.
Effect of TNFα on Mitochondrial Function in Human Airway Smooth Muscle
Chen, X., Seekar, P., Delmotte, P. , Chen, Xuejun , Mathieu, Natalia M. , Sieck, Gary C.

Mayo Clinic

A63. PATHOPHYSIOLOGY OF ASTHMA IN CELLS, TISSUES, AND ANIMAL MODELS | August 26, 2019 | Volume: No volume available | Issue: No issue available | Pages: A2197-A2197

10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a2197 Get It

TNFα Induces Endoplasmic Reticulum Stress in Human Airway Smooth Muscle Cells
Yap, John Q. , Chen, Xuejun , Delmotte, Philippe , Marin, Natalia Mathieu, Sieck, G.C.

Mayo Clinic

A63. PATHOPHYSIOLOGY OF ASTHMA IN CELLS, TISSUES, AND ANIMAL MODELS | August 26, 2019 | Volume: No volume available | Issue: No issue available | Pages: A2173-A2173

10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a2173 Get It

TNFα Increases Mitochondrial Biogenesis in Human Airway Smooth Muscle
Chen, Xing , Delmotte, P. , Mathieu, Natalia M. , Sieck, Gary C.

Mayo Clinic

A63. PATHOPHYSIOLOGY OF ASTHMA IN CELLS, TISSUES, AND ANIMAL MODELS | August 26, 2019 | Volume: No volume available | Issue: No issue available | Pages: A2172-A2172

10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a2172 Get It

Open Versus Robotic Cystectomy: A Propensity Score Matched Analysis Comparing Survival Outcomes
Moschini, Marco , Zamboni, Stefania , Mathiéu, Romain , Xylinas, Évanguelos , Tan, Wei Shen , Kelly, John D. , Simone, Giuseppe , Meraney, Anoop, Krishna, Suprita, Konety, Badrinath R. , Mattei, Agostino , Baumeister, Philipp , Mordasini, Livio , Montorsi, Francesco , Briganti, Alberto , Sanchez‐Salas, Rafael , Cathelineau, Xavier , Rink, Michael , Karakiewicz, Pierre I. , Koupparis, Anthony , Kassouf, Wassim , Scherr, Douglas S. , Ploussard, Guillaume , Boorjian, Stephen A. , Sooriakumaran, Prasanna , Larcher, Alessandro , Simone, Giuseppe , Gallina, Andrea , Lotan, Yair , Moschini, Marco , Soria, Francesco , Baumeister, Philipp, Gallina, Andrea , Stabile, Armando , Necchi, Andrea , Rouprêt, Morgan , Lotan, Yair , Shariat, Shahrokh F.

Mayo Clinic

Journal of Clinical Medicine | August 9, 2019 | Volume: 8 | Issue: 8 | Pages: 1192

10.3390/jcm8081192 | PMID 31395826 Get It

Background: To assess the differential effect of robotic assisted radical cystectomy (RARC) versus open radical cystectomy (ORC) on survival outcomes in matched analyses performed on a large multicentric cohort. Methods: The study included 9757 patients with urothelial bladder cancer (BCa) treated in a consecutive manner at each of 25 institutions. All patients underwent radical cystectomy with bilateral pelvic lymphadenectomy. To adjust for potential selection bias, propensity score matching 2:1 was performed with two ORC patients matched to one RARC patient. The propensity-matched cohort included 1374 patients. Multivariable competing risk analyses accounting for death of other causes, tested association of surgical technique with recurrence and cancer specific mortality (CSM), before and after propensity score matching. Results: Overall, 767 (7.8%) patients underwent RARC and 8990 (92.2%) ORC. The median follow-up before and after propensity matching was 81 and 102 months, respectively. In the overall population, the 3-year recurrence rates and CSM were 37% vs. 26% and 34% vs. 24% for ORC vs. RARC (all p values > 0.1), respectively. On multivariable Cox regression analyses, RARC and ORC had similar recurrence and CSM rates before and after matching (all p values > 0.1). Conclusions: Patients treated with RARC and ORC have similar survival outcomes. This data is helpful in consulting patients until long term survival outcomes of level one evidence is available.
Trans-endocytosis elicited by nectins transfers cytoplasmic cargo, including infectious material, between cells
Generous, Alex R., Harrison, O.J. , Troyanovsky, Regina B. , Mateo, Mathieu , Navaratnarajah, Chanakha K. , Donohue, Ryan C. , Pfaller, Christian K. , Alekhina, Olga , Sergeeva, Alina P. , Indra, Indrajyoti , Thornburg, Theresa, Kochetkova, Irina , Billadeau, Daniel D. , Troyanovsky, Sergey M. , Honig, Barry , Shapiro, Lawrence , Cattaneo, Roberto , Cattaneo, Roberto , Pfaller, Christian K , Taylor, Matthew P.

Mayo Clinic

Journal of Cell Science | July 22, 2019 | Volume: 132 | Issue: 16 | Pages: No page available

10.1242/jcs.235507 | PMID 31331966 Get It

ABSTRACT Here, we show that cells expressing the adherens junction protein nectin-1 capture nectin-4-containing membranes from the surface of adjacent cells in a trans-endocytosis process. We find that internalized nectin-1–nectin-4 complexes follow the endocytic pathway. The nectin-1 cytoplasmic tail controls transfer: its deletion prevents trans-endocytosis, while its exchange with the nectin-4 tail reverses transfer direction. Nectin-1-expressing cells acquire dye-labeled cytoplasmic proteins synchronously with nectin-4, a process most active during cell adhesion. Some cytoplasmic cargo remains functional after transfer, as demonstrated with encapsidated genomes of measles virus (MeV). This virus uses nectin-4, but not nectin-1, as a receptor. Epithelial cells expressing nectin-4, but not those expressing another MeV receptor in its place, can transfer infection to nectin-1-expressing primary neurons. Thus, this newly discovered process can move cytoplasmic cargo, including infectious material, from epithelial cells to neurons. We name the process nectin-elicited cytoplasm transfer (NECT). NECT-related trans-endocytosis processes may be exploited by pathogens to extend tropism. This article has an associated First Person interview with the first author of the paper.
SUN-373 Small Adrenal Incidentaloma Stable in Size Becoming a Stage IV Adrenocortical Carcinoma 10 Years Later in a Young Patient Carrying a Germline APC Variant of Uncertain Significance (VUS)
Boily, Pascale, Gagnon, Nadia , Alguire, Catherine, Corbeil, Gilles, Latour, Mathieu, Beauregard, Catherine, Nolet, Serge, Caceres, Katia, Haffaf, Zaki El , Olney, Harold J., Bourdeau, Isabelle , Bancos, Irina , Saad, Fred

Mayo Clinic

Journal of the Endocrine Society | May 10, 2019 | Volume: 3 | Issue: Supplement_1 | Pages: No page available

10.1210/js.2019-sun-373 Get It